Details for Patent: 5,637,611
✉ Email this page to a colleague
Title: | Medicaments |
Abstract: | Use of a compound of general formula (I): ##STR1## wherein: R.sup.1 represents hydrogen, halogen, trifluoromethyl, nitro, hydroxy, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, arylC.sub.1-6 alkoxy, --CO.sub.2 R.sup.4, --(CH.sub.2).sub.n CN, --(CH.sub.2).sub.n CONR.sup.5 R.sup.6, --(CH.sub.2).sub.n SO.sub.2 NR.sup.5 R.sup.6, C.sub.1-6 alkanoylamino (CH.sub.2).sub.n, or C.sub.1-6 alkylsulphonylamino (CH.sub.2).sub.n ; R.sup.4 represents hydrogen, C.sub.1-6 alkyl or arylC.sub.1-6 alkyl; R.sup.5 and R.sup.6 each independently represent hydrogen or C.sub.1-6 alkyl, or R.sup.5 and R.sup.6 together with the nitrogen atom to which they are attached form a ring; n represents 0, 1 or 2; and R.sup.2 and R.sup.3 each independently represent hydrogen, C.sub.1-6 alkyl or benzyl or together with the nitrogen atom to which they are attached form a pyrrolidino, piperidino or hexahydroazepino ring; or a physiologically acceptable salt thereof, in the manufacture of a medicament for the treatment of a condition where a 5-HT.sub.1 -like agonist is indicated, for example migraine. Novel compounds of formula (I), processes for preparing them and pharmaceutical compositions containing them are also described. |
Inventor(s): | King; Francis D. (Harlow, GB2), Gaster; Laramie M. (Harlow, GB2), Kaumann; Alberto J. (Trumpington, GB2), Young; Rodney C. (Hertford, GB2) |
Assignee: | SmithKline Beecham p.l.c. (GB2) |
Filing Date: | May 15, 1995 |
Application Number: | 08/442,719 |
Claims: | 1. A compound of the general formula (I): ##STR9## wherein: R.sup.1 is a group --(CH.sub.2).sub.n CONR.sup.5 R.sup.6 ; n is zero; R.sup.5 and R.sup.6 each independently represent hydrogen, methyl, ethyl or propyl; and R.sup.2 and R.sup.3 each independently represent hydrogen or C.sub.1-6 alkyl provided both are not hydrogen; or a pharmaceutically acceptable salt thereof. 2. A compound of claim 1 wherein R.sup.2 and R.sup.3 each independently represent hydrogen, methyl or ethyl. 3. A compound of claim 2 wherein R.sup.5 and R.sup.6 each independently represent hydrogen or methyl. 4. A compound of claim 1, which is selected from 3-n-propylamino-6-carboxamido- 1,2,3,4-tetrahydrocarbazole; 3-i-propylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or a salt thereof. 5. A compound of claim 1, which is selected from 3-(N-(methyl)ethylamino)-6-carboxamido-1,2,3,4-tetrahydrocarbazole; 3-dimethylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole; 3-ethylamino-6-carboxamido- 1,2,3,4-tetrahydrocarbazole; or a pharmaceutically acceptable salt thereof. 6. 3-Benzylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole; or salt thereof. 7. 3-Pyrrolidinyl-6-carboxamido-1,2,3,4-tetrahydrocarbazole, or salt thereof. 8. A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier. 9. A pharmaceutical composition comprising a compound of claim 3 or a pharmaceutically acceptable salt thereof, and a physiologically acceptable carrier. 10. A method of treatment of a condition wherein a 5-HT.sub.1 -like agonist is indicated, which comprises administering to a subject in need thereof an effective amount of a compound of claim 1. 11. A method of claim 10 wherein in a compound of formula (I) R.sup.5 and R.sup.6 each independently represent hydrogen and methyl and R.sup.1 and R.sup.2 each represent hydrogen, methyl or ethyl provided R.sup.1 and R.sup.2 are not both hydrogen. |